
In Entwicklung
Gesundheit·01.06.2026KI-Zusammenfassung
Ivonescimab Trial Shows Significant Survival Benefit in Lung Cancer
Ivonescimab's phase three trial showed a 34% reduction in death risk for non-small cell lung cancer patients. Despite positive results, its shares dropped 1.86% in Hong Kong.
S
SCMP Tech